These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18159594)

  • 1. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
    Cho KS; Oh HY; Lee EJ; Hong SJ
    Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
    Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
    Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
    Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
    Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
    Ogata R; Matsueda S; Yao A; Noguchi M; Itoh K; Harada M
    Prostate; 2004 Sep; 60(4):273-81. PubMed ID: 15264237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative multi-gene expression profiling of primary prostate cancer.
    Schmidt U; Fuessel S; Koch R; Baretton GB; Lohse A; Tomasetti S; Unversucht S; Froehner M; Wirth MP; Meye A
    Prostate; 2006 Oct; 66(14):1521-34. PubMed ID: 16921506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EZH2 expression in human prostate cancer and its clinicopathologic significance].
    Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L
    Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma.
    Bachmann N; Haeusler J; Luedeke M; Kuefer R; Perner S; Assum G; Paiss T; Hoegel J; Vogel W; Maier C
    Cancer Genet Cytogenet; 2008 Apr; 182(2):103-10. PubMed ID: 18406871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
    Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
    Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
    Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of cytokeratin 20 mRNA in the peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymeras chain reaction.
    Guo J; Xiao B; Jin Z; Qin L; Chen J; Chen H; Zhang X; Liu Z
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1279-84. PubMed ID: 16048578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
    Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
    Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of positive and negative immunomagnetic isolation followed by real-time RT-PCR for detection of the circulating tumor cells in patients with colorectal cancers.
    Guo J; Xiao B; Zhang X; Jin Z; Chen J; Qin L; Mao X; Shen G; Chen H; Liu Z
    J Mol Med (Berl); 2004 Nov; 82(11):768-74. PubMed ID: 15490093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
    Fang J; Zhang M; Li Q
    Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
    Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
    Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
    Choi JH; Song YS; Yoon JS; Song KW; Lee YY
    APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.